National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overPharmaceutical / IndustryA4021016
NCT00596830

Trial Description

Summary

Determine whether the addition of CP 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.

Eligibility Criteria

Inclusion Criteria:

  • Confirmed diagnosis of non small cell lung cancer with a primary histology of predominantly squamous cell, large cell or adenosquamous carcinoma.
  • Advanced NSCLC with documented Stage IIIB (with pleural effusion) or Stage IV or recurrent disease.
  • No prior systemic treatment for NSCLC, except for adjuvant chemotherapy. Adjuvant chemotherapy must have completed for greater than or equal to 12 months prior to randomization.
  • Prior surgery or radiation therapy is permitted if completed at least 3 weeks prior to randomization and all acute toxicities have resolved.
  • ECOG performance status (PS) 0 or 1.

Exclusion Criteria:

  • Patients with symptomatic central nervous system (CNS) metastases are not permitted.
  • Patients requiring chronic steroid use or patients with uncontrolled diabetes are not permitted.
  • Patients with other active cancer types are not permitted.

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call CenterStudy Director

Pfizer Oncology Clinical Trial Information ServicePh: 1-877-369-9753
  Email: PfizerCancerTrials@emergingmed.com

Pfizer CT.gov Call CenterPh: 1-800-718-1021

Trial Sites

U.S.A.
Alabama
  Florence
 Pfizer Investigational Site
  Huntsville
 Pfizer Investigational Site
  Muscle Shoals
 Pfizer Investigational Site
Arkansas
  Fort Smith
 Pfizer Investigational Site
  Hot Springs
 Pfizer Investigational Site
Colorado
  Aurora
 Pfizer Investigational Site
  Boulder
 Pfizer Investigational Site
  Colorado Springs
 Pfizer Investigational Site
  Denver
 Pfizer Investigational Site
  Lakewood
 Pfizer Investigational Site
  Littleton
 Pfizer Investigational Site
  Lone Tree
 Pfizer Investigational Site
  Longmont
 Pfizer Investigational Site
  Parker
 Pfizer Investigational Site
  Thornton
 Pfizer Investigational Site
Connecticut
  Norwich
 Pfizer Investigational Site
District of Columbia
  Washington
 Pfizer Investigational Site
Florida
  Boynton Beach
 Pfizer Investigational Site
  Hollywood
 Pfizer Investigational Site
  Jacksonville
 Pfizer Investigational Site
  Lake City
 Pfizer Investigational Site
  Lake Worth
 Pfizer Investigational Site
  Pembroke Pines
 Pfizer Investigational Site
  PENSACOLA
 Pfizer Investigational Site
  Pensacola
 Pfizer Investigational Site
  Port St. Lucie
 Pfizer Investigational Site
Georgia
  Atlanta
 Pfizer Investigational Site
  Conyers
 Pfizer Investigational Site
  Cumming
 Pfizer Investigational Site
  Decatur
 Pfizer Investigational Site
  Duluth
 Pfizer Investigational Site
  Lawrenceville
 Pfizer Investigational Site
  Macon
 Pfizer Investigational Site
  Marietta
 Pfizer Investigational Site
  Roswell
 Pfizer Investigational Site
  Snellville
 Pfizer Investigational Site
  Stockbridge
 Pfizer Investigational Site
Idaho
  Coeur d' Alene
 Pfizer Investigational Site
Illinois
  Arlington Heights
 Pfizer Investigational Site
  Aurora
 Pfizer Investigational Site
  Elk Grove Village
 Pfizer Investigational Site
  Galesburg
 Pfizer Investigational Site
  Skokie
 Pfizer Investigational Site
Indiana
  Avon
 Pfizer Investigational Site
  Beech Grove
 Pfizer Investigational Site
  Hobart
 Pfizer Investigational Site
  Indianapolis
 Pfizer Investigational Site
  Mooresville
 Pfizer Investigational Site
  Munster
 Pfizer Investigational Site
Iowa
  Cedar Rapids
 Pfizer Investigational Site
Kansas
  Kansas City
 Pfizer Investigational Site
  Overland Park
 Pfizer Investigational Site
Kentucky
  Louisville
 Pfizer Investigational Site
Louisiana
  New Orleans
 Pfizer Investigational Site
Maryland
  Bethesda
 Pfizer Investigational Site
Minnesota
  St. Louis Park
 Pfizer Investigational Site
Mississippi
  Columbus
 Pfizer Investigational Site
  Corinth
 Pfizer Investigational Site
  Oxford
 Pfizer Investigational Site
  Southaven
 Pfizer Investigational Site
  Tupelo
 Pfizer Investigational Site
Missouri
  Kansas City
 Pfizer Investigational Site
  Lee's Summit
 Pfizer Investigational Site
Nebraska
  Lincoln
 Pfizer Investigational Site
  Omaha
 Pfizer Investigational Site
Nevada
  Las Vegas
 Pfizer Investigational Site
New York
  Lake Success
 Pfizer Investigational Site
  Manhasset
 Pfizer Investigational Site
  New Hyde Park
 Pfizer Investigational Site
  Oneida
 Pfizer Investigational Site
  Oswego
 Pfizer Investigational Site
  Syracuse
 Pfizer Investigational Site
North Carolina
  Burlington
 Pfizer Investigational Site
Ohio
  Canton
 Pfizer Investigational Site
  Cleveland
 Pfizer Investigational Site
  Dover
 Pfizer Investigational Site
Oklahoma
  Norman
 Pfizer Investigational Site
  Oklahoma City
 Pfizer Investigational Site
  Tulsa
 Pfizer Investigational Site
Pennsylvania
  Allentown
 Pfizer Investigational Site
  Bethlehem
 Pfizer Investigational Site
  Philadelphia
 Pfizer Investigational Site
  Radnor
 Pfizer Investigational Site
Tennessee
  Bartlett
 Pfizer Investigational Site
  Collierville
 Pfizer Investigational Site
  Knoxville
 Pfizer Investigational Site
  Maryville
 Pfizer Investigational Site
  Memphis
 Pfizer Investigational Site
Texas
  Fort Worth
 Pfizer Investigational Site
  Grapevine
 Pfizer Investigational Site
  Irving
 Pfizer Investigational Site
  San Antonio
 Pfizer Investigational Site
  Southlake
 Pfizer Investigational Site
Utah
  Bountiful
 Pfizer Investigational Site
  Layton
 Pfizer Investigational Site
  Murray
 Pfizer Investigational Site
  Provo
 Pfizer Investigational Site
  Salt Lake City
 Pfizer Investigational Site
  West Valley City
 Pfizer Investigational Site
Washington
  Seattle
 Pfizer Investigational Site
Australia
New South Wales
  Port Macquarie
 Pfizer Investigational Site
Victoria
  Geelong
 Pfizer Investigational Site
Austria
  Linz
 Pfizer Investigational Site
  Wien
 Pfizer Investigational Site
Canada
Alberta
  Edmonton
 Pfizer Investigational Site
Quebec
  Levis
 Pfizer Investigational Site
Czech Republic
  Nova Ves pod Plesi
 Pfizer Investigational Site
  Praha 8
 Pfizer Investigational Site
  Pribram I
 Pfizer Investigational Site
Finland
  Helsinki
 Pfizer Investigational Site
  Pori
 Pfizer Investigational Site
France
  Caen Cedex
 Pfizer Investigational Site
  Caen Cedex 05
 Pfizer Investigational Site
  Clermond-Ferrand Cedex 01
 Pfizer Investigational Site
  DIJON
 Pfizer Investigational Site
  Lyon Cedex 04
 Pfizer Investigational Site
  Nantes Cedex 2
 Pfizer Investigational Site
  Rennes Cedex 9
 Pfizer Investigational Site
  Saint Herblain Cedex
 Pfizer Investigational Site
  Saint Pierre la Réunion Cedex
 Pfizer Investigational Site
Germany
  Karlsruhe
 Pfizer Investigational Site
  Mainz
 Pfizer Investigational Site
Greece
  Athens
 Pfizer Investigational Site
Hong Kong
  Shatin, New Territories
 Pfizer Investigational Site
  Tuen Mun
 Pfizer Investigational Site
Hungary
  Budapest
 Pfizer Investigational Site
  Deszk
 Pfizer Investigational Site
  Szekesfehervar
 Pfizer Investigational Site
  Szombathely
 Pfizer Investigational Site
  Torokbalint
 Pfizer Investigational Site
India
  Bangalore
 Pfizer Investigational Site
  Nagpur
 Pfizer Investigational Site
  Navrangpura / Ahmedabad
 Pfizer Investigational Site
Ireland
  Dublin
 Pfizer Investigational Site
Italy
  Genova
 Pfizer Investigational Site
  Orbassano (TO)
 Pfizer Investigational Site
  Roma
 Pfizer Investigational Site
Poland
  Krakow
 Pfizer Investigational Site
  Warszawa
 Pfizer Investigational Site
  Wroclaw
 Pfizer Investigational Site
Puerto Rico
  Ponce
 Pfizer Investigational Site
Republic of Bulgaria
  Sofia
 Pfizer Investigational Site
  SOFIA
 Pfizer Investigational Site
  Varna
 Pfizer Investigational Site
Republic of Korea
  Gyeonggi-do
 Pfizer Investigational Site
  Seoul
 Pfizer Investigational Site
Russia
  Moscow
 Pfizer Investigational Site
  Saint-Petersburg
 Pfizer Investigational Site
  Sochi
 Pfizer Investigational Site
  St. Petersburg
 Pfizer Investigational Site
  St-Petersburg
 Pfizer Investigational Site
Slovakia
  Nitra-Zobor
 Pfizer Investigational Site
  Nove Zamky
 Pfizer Investigational Site
Spain
  CORDOBA
 Pfizer Investigational Site
  L'HOSPITALET DE LLOBREGAT
 Pfizer Investigational Site
  MADRID
 Pfizer Investigational Site
  PAMPLONA
 Pfizer Investigational Site
  SANTANDER
 Pfizer Investigational Site
  VALENCIA
 Pfizer Investigational Site
Switzerland
  Fribourg
 Pfizer Investigational Site
  Zuerich
 Pfizer Investigational Site
Taiwan, Province of China
  Tainan
 Pfizer Investigational Site
  Taipei
 Pfizer Investigational Site
Turkey
  Ankara
 Pfizer Investigational Site
  Sihhiye
 Pfizer Investigational Site
Ukraine
  Dnipropetrovsk
 Pfizer Investigational Site
  Kyiv
 Pfizer Investigational Site
  Lviv
 Pfizer Investigational Site
  Sumy
 Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00596830
Information obtained from ClinicalTrials.gov on May 13, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov